DYNE THERAPEUTICS INC (DYN)
Health Care · biotechnology · NASDAQ
Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform.
What DYNE THERAPEUTICS INC does
Dyne Therapeutics is a biotechnology company focused on advancing its proprietary FORCE platform to develop targeted muscle therapeutics for patients with serious muscle diseases. The company is in the research and development stage, working to address unmet needs in rare genetic muscle conditions.
Themes: rare disease therapeutics, genetic muscle disorders, drug development platform
Fundamentals
- Price$16.37 as of 2026-10-08 close
- Market cap$3.1B as of 2026-07-24 (share count; price 2026-10-08)
- 1-year return+12.4% 2025-10-08 close $14.56 → 2026-10-08 close $16.37
- P/En/a negative earnings
- ROE-45.9% FY2025, SEC XBRL
- Debt / equity0.30 as of 2026-09-03
- Beta1.72 as of 2026-09-03
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
How DYN compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How DYNE THERAPEUTICS INC looks technically
DYNE THERAPEUTICS INC (DYN) is trading 16.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 249 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 53, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive). It made a new 20-day low about 5 trading days ago. It is 40.0% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 16.3% below its 200-day average, the long-term trend line — a long-term downtrend | -16.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $21.76 | $21.76 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $19.56 | $19.56 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 249 trading days ago — a "golden cross", a bullish long-term signal | 249 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 53, with sellers in control | 52.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 35.1 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($14.93 to $17.59) — its "stochastic" reading is 54 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 54.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $27.30 | $27.30 |
|---|---|---|
| From the 52-week high | it is 40.0% below its 52-week high (its highest price of the past year) | -40.0% |
| Above the 52-week low | it is 31.7% above its 52-week low (its lowest price of the past year) | +31.7% |
| Below the 52-week high | it is 40.0% below its highest point of the past year | 40.0% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $47.45 (set on 2024-08-20) | $47.45 |
| Given back of the 52-week move | over the past year its closes ranged ($12.65 to $26.78), and it has given back well over two thirds of its rise from last year’s low — 74% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.60 to $18.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 73.7% |
| From the all-time high | it is 65.5% below its all-time high | -65.5% |
| Nearest price level | it is trading 2.5% above a support level at $15.96 — a price it turned at three times since 2025-10-23, most recently on 2026-05-19. Since 2024-10-08 it has 5 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.5% |
| All-time low | its lowest closing price on record is $4.30 (set on 2022-06-02) | $4.30 |
| Above the all-time low | it is 280.7% above its all-time low | +280.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9583 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9583 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $14.75 and $18.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $14.75 – $16.65 – $18.55 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 3.3 daily ranges below its 200-day average price (16.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.87× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.7% since the prior reading | -0.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
4
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Open gap | it gapped 4.6% below the previous close 21 sessions ago and has not traded back through the level it left behind at 20.31 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -4.6% |
| Gap filled | a 3.4% gap up opened on 2026-09-17 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 14 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +6.3% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 20.4 percentage points (the stock lost 19.4% while the market gained 1.0%) | -20.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 35.1 percentage points (the stock lost 31.3% while the market gained 3.8%) | -35.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 28.2 percentage points (the stock lost 10.8% while the market gained 17.5%) | -28.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 2.5 percentage points (the stock gained 12.4% while the market gained 15.0%) | -2.5% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 30% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 15.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -29.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $19.52 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -16.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is under water. That average is $20.41 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -19.8% |
Price levels it has turned at before
DYN last closed at $16.37 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.96 | Support | 2.5% below the last close | turned there three times · 2025-10-23 to 2026-05-19 |
| $17.01 | Resistance | 3.9% above the last close | turned there five times · 2025-02-06 to 2026-09-08 |
| $14.48 | Support | 11.6% below the last close | turned there three times · 2025-02-21 to 2026-02-20 |
| $18.32 | Resistance | 11.9% above the last close | turned there twice · 2025-12-09 to 2025-12-18 |
| $13.99 | Support | 14.5% below the last close | turned there twice · 2025-09-18 to 2026-03-02 |
| $19.43 | Resistance | 18.7% above the last close | turned there three times · 2026-02-03 to 2026-05-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · lagging the market · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.35 mean, 1=Strong Buy…5=Strong Sell) — 15 analysts
- Mean price target$35.73 range $10.00 – $50.00; median $37.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DYN
- Consensus EPS estimate-$0.8876 next reporting period, as of 2026-10-08
- Estimate change, 30 days-$0.00914 from -$0.8785, on 2026-09-03, 35-day window
- Readings revised upward17% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the success of the FORCE platform and clinical trial outcomes.","Significant capital requirements and the need for potential future financing.","Strict regulatory requirements and risks associated with obtaining clinical and commercial approvals."]
What changed in the latest 10-Q
AI-assisted comparison of DYN's 10-Q filed 2026-07-29 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states z-rostudirsen is being evaluated in the long-term extension portion of the DELIVER trial and the FORZETTO trial, whereas older filing only mentioned the DELIVER trial.
- Newer filing states the registrational expansion cohort of the DELIVER trial met its primary endpoint.
- Newer filing states data from the DELIVER trial served as the basis for a BLA for potential U.S. Accelerated Approval.
- Newer filing includes detailed description of the FORZETTO Phase 3 trial initiated in May 2026, including enrollment of approximately 90 participants ages 4 to 18, 1:1 randomization to 20 mg/kg z-rostudirsen or placebo Q4W, primary endpoint of RFF velocity at Week 73, secondary endpoints (SV95C, NSAA, 10MWR, 4SC, FVC%p), 72-week double-blind period followed by 96-week open-label extension, and intended role as confirmatory trial.
- Newer filing states in July 2026 the FDA accepted the BLA for z-rostudirsen with priority review and a PDUFA target action date of January 21, 2027.
- Newer filing states dosing of patients in the HARMONIA trial began in July 2026.
- Newer filing includes detailed description of the HARMONIA Phase 3 trial parameters: approximately 150 participants age 16 and older, 1:1 randomization to 6.8 mg/kg z-basivarsen or placebo Q8W, primary endpoint of 5xSTS at week 49, secondary endpoints (video hand opening time, quantitative muscle testing, 10MWR, Myotonic Dystrophy Health Index, additional patient- and clinician-reported outcomes), exploratory CNS endpoints, 48-week double-blind period followed by 24-week open-label extension.
- Removed:
- Older filing stated the company planned to submit a BLA to the FDA for U.S. Accelerated Approval in the second quarter of 2026 based on dystrophin as a surrogate endpoint following a positive pre-BLA meeting.
- Older filing stated the company planned to initiate a global confirmatory Phase 3 clinical trial of z-rostudirsen in the second quarter of 2026.
- Older filing stated the company reached its enrollment target of 60 participants in the registrational expansion cohort of the ACHIEVE trial, planned to allow participants in screening to enroll, expected to complete enrollment of more than 60 participants in Q2 2026, planned to announce REC data in Q1 2027 to support a potential BLA submission early in Q3 2027, and anticipated a potential U.S. launch in Q1 2028.
- Reworded:
- Newer filing changed z-rostudirsen regulatory status from a planned future BLA submission to a submitted and accepted BLA.
- Newer filing changed the description of the DELIVER trial from ongoing evaluation to long-term extension portion evaluation.
- Newer filing changed the HARMONIA trial description from 'initiated in March 2026' to include dosing start in July 2026.
- Newer filing removed the statement that U.S. launch expectations for z-rostudirsen assume FDA grants priority review; instead states priority review already granted.
- Notes:
- The newer filing text appears truncated at the end of the HARMONIA section; comparison beyond that point was not possible for subsequent sections (FSHD, Pompe, and later financial discussion) because the provided newer excerpt ends mid-sentence.
- The older filing text also appears truncated; the FSHD and Pompe sections present in the older text do not appear in the provided newer text excerpt, but this may be due to truncation of the provided material rather than actual removal in the filing.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 17 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-05. The 4 days since 2026-10-05 have not been checked yet.
- Last 30 days · read to 2026-10-051 buy ($40000) · 0 sells — 1 buying insider
- Last 90 days · read to 2026-10-051 buy ($40000) · 17 sells ($72M) — 1 buying, 6 selling insiders
- Last 180 days · read to 2026-10-055 buys ($196800) · 110 sells ($153M) — 1 buying, 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-02. Based on Form 4 filings read through 2026-10-05; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DYN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding DYN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 33,805,081
- Reported value $750,810,846
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about DYN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
DYN had 23,381,047 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
DYN had 12.5% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.46 days to cover at the same settlement.
- Reported short interest (shares) 23,381,047
- Short interest (% of shares outstanding) 12.5%
- Prior settlement (shares) 20,790,669
- Reported change 12.46%
- Days to cover (reported) 5.46
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
DYNE THERAPEUTICS INC is found in…
Frequently asked questions
What does DYNE THERAPEUTICS INC (DYN) do?
Dyne Therapeutics is a biotechnology company focused on advancing its proprietary FORCE platform to develop targeted muscle therapeutics for patients with serious muscle diseases. The company is in the research and development stage, working to address unmet needs in rare genetic muscle conditions.
What sector is DYNE THERAPEUTICS INC (DYN) in?
DYNE THERAPEUTICS INC (DYN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Is DYNE THERAPEUTICS INC (DYN) overbought or oversold right now?
DYNE THERAPEUTICS INC (DYN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DYN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.